Search Bar & Filters
Found 17 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating treatments for germinal center B-cell-like diffuse large B-cell lymphoma GCB DLBCL, a fast-growing blood cancer affecting immature B-cells. The study aims to determine if more people respond to zilovertamab vedotin MK-2140 combined with R-CHP compared to polatuzumab vedotin combined with R-CHP. This is a phase 2 randomized study focused on participants who have not been treated before and have the GCB subtype of DLBCL. Participants will be randomly assigned to receive either zilovertamab vedotin plus cyclophosphamide, doxorubicin, rituximab or its biosimilar R-CHP, or polatuzumab vedotin plus R-CHP. These drugs are given by intravenous infusion on Day 1 of each 3-week cycle for up to 6 cycles, about 4 months. Additionally, participants take prednisone or prednisolone tablets daily on Days 1 to 5 of each cycle. Those with high-risk DLBCL may receive 2 extra cycles of rituximab or its biosimilar. Throughout the study, participants undergo assessments including PET scans to monitor cancer response, and various health evaluations. Researchers measure complete response rate at the end of treatment, progression-free survival, overall survival, event-free survival, and quality of life using standardized tools. Safety is monitored by tracking adverse events and treatment tolerability. The study lasts up to several years with follow-up for long-term outcomes.
Actively Recruiting
Researchers are studying two surgical procedures to reduce the risk of ovarian cancer in women with BRCA1 genetic mutations. This trial compares bilateral salpingectomy, which removes only the fallopian tubes, with bilateral salpingo-oophorectomy, which removes both fallopian tubes and ovaries. The goal is to find out if removing just the fallopian tubes with delayed ovary removal is nearly as effective as removing both from the start. Participants choose between two groups one undergoes bilateral salpingectomy with the option of later ovary removal, and the other undergoes bilateral salpingo-oophorectomy. Both groups have imaging tests like pelvic ultrasounds or pelvic MRIs during screening and provide blood samples throughout the study. Follow-up visits occur at multiple time points, including 10 to 60 days, 6 months, 12 months, 24 months, and then yearly for up to 20 years. During the study, researchers track if ovarian or related cancers develop and assess symptoms related to estrogen loss, quality of life, cancer-related distress, sexual function, menopausal symptoms, medical decision making, and any adverse events. Various questionnaires and imaging tests support these evaluations. Long-term safety and cancer risk reduction are monitored for up to two decades after surgery.
Actively Recruiting
Researchers are evaluating the use of a dexamethasone mouthwash to prevent stomatitis, a painful mouth condition, in patients receiving Datopotamab Deruxtecan Dato-DXd treatment for certain types of breast cancer or EGFR-mutated non-small cell lung cancer. This Phase IV study focuses on the incidence and severity of grade 2 or higher stomatitis within the first 12 weeks of Dato-DXd treatment. The study involves two groups one with breast cancer and the other with lung cancer, enrolling about 100 participants in total. Participants will use an alcohol-free dexamethasone mouthwash, 0.5 mg per 5 mL, four times daily by swishing 10 mL for about 2 minutes and then spitting it out without swallowing. They must avoid food or drink for at least 30 minutes after use. This mouthwash will be used throughout their standard care treatment with Dato-DXd. The study will follow participants for at least 12 weeks after starting treatment, with additional safety monitoring for about 21 months. During the study, participants will be assessed for the occurrence and severity of stomatitis, adherence to mouthwash use, and any dose changes of Dato-DXd due to stomatitis. Researchers will monitor safety and tolerability of the treatment combination through clinical evaluations, including documentation of side effects. Participants will be followed for safety up to 28 days after their last dose and may be monitored for up to 21 months to observe long-term outcomes.
Actively Recruiting
Healthy Volunteer
Researchers are conducting an observational case-control study to evaluate a genome-wide methylome enrichment platform using cell-free DNA cfDNA to detect multiple cancer types and distinguish among them. The study focuses on common and deadly cancers, including brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid cancers. It also aims to assess the platforms ability to detect minimal residual disease and early relapse in lung cancer after treatment. Participants include individuals newly diagnosed with cancer and controls without known cancer. All participants provide a blood sample and clinical data at enrollment. Those with stage I-III lung cancer have additional blood draws and clinical follow-up after completing first-line treatment every three months for the first year, then every six months for two more years. Other cancer cases have annual clinical follow-up for three years. Controls are followed every six months for up to three years. The study uses a sensitive, bisulfite-free DNA methylation profiling assay enriched for methylated CpGs from cfDNA, followed by high-throughput sequencing. Participants provide blood samples and clinical information at baseline and during follow-up. The research team tracks cancer detection, tissue of origin, and clinical outcomes over time without sharing test results with participants or clinicians. Follow-up schedules vary by group and last up to three years or more depending on cancer type. The study measures cancer detection at 24 months and clinical outcomes at 54 months, aiming to improve early cancer detection and monitoring through this advanced liquid biopsy technology.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
Actively Recruiting
Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.
Actively Recruiting
Researchers are collecting clinical data and biological samples from adults diagnosed with stage I, stage II, or operable stage III cancers in certain solid tumor types. This observational study aims to help develop tests that improve cancer detection and assess the risk of cancer returning. Participants continue to receive standard care from their own doctors throughout the study. Participants will provide blood and tumor tissue samples during their routine care. The study includes several tumor groups such as bladder cancer, esophageal cancer, gastric and gastroesophageal junction cancer, melanoma, non-small cell lung cancer, pancreatic cancer, and a mix of other solid tumors. Enrollment occurs either before or within three months after surgery, and no prior systemic therapy for the current cancer is allowed before joining. During the approximately five and a half years of involvement, participants will be observed with collection of blood and tissue samples as part of a biospecimen registry. Researchers will use this information to study molecular residual disease in solid tumors. All clinical data and samples will be gathered under routine care settings, with no additional treatment provided by the study team.
Actively Recruiting
Researchers are evaluating whether simply observing patients after surgery is as effective as continuing pembrolizumab treatment in preventing cancer recurrence in people with early-stage triple-negative breast cancer TNBC who had a complete response after receiving chemotherapy plus pembrolizumab before surgery. This Phase III trial aims to determine if stopping pembrolizumab post-surgery can maintain recurrence-free survival while potentially improving quality of life and reducing treatment burden. Participants are randomly assigned to one of two groups after finishing chemotherapy with pembrolizumab and surgery. One group continues pembrolizumab intravenously every 3 or 6 weeks for 27 weeks. The other group undergoes observation without further pembrolizumab for the same period. Throughout the study, patients have tumor biopsies and blood collected, along with imaging such as mammography, breast ultrasound, or MRI during follow-up. Participants will be monitored for recurrence-free survival and overall survival for up to 10 years. The study also assesses adverse events, quality of life, financial impact, and work productivity at about 27 weeks after starting the assigned treatment or observation. Safety and treatment effects are tracked through biopsies, imaging, blood tests, and patient questionnaires during the study and follow-up.
Actively Recruiting
Researchers are evaluating pumitamig BNT327 combined with chemotherapy etoposidecarboplatin compared to atezolizumab combined with the same chemotherapy for participants with previously untreated extensive-stage small-cell lung cancer. This Phase III, multisite, randomized, double-blinded study aims to compare these treatments to better understand options for first-line ES-SCLC therapy. The study has two stages involving different treatment arms. Stage 1 includes two pumitamig doses combined with chemotherapy and one control arm with atezolizumab plus chemotherapy. Stage 2 has one pumitamig dose treatment arm and a control arm with atezolizumab plus chemotherapy. Participants receive intravenous infusions of study drugs, with the option to switch from carboplatin to cisplatin if needed. Each stage has a screening period up to 21 days, followed by induction and maintenance treatment until disease progression, intolerable side effects, withdrawal, study end, or up to 2 years, then a safety and survival follow-up period. Participants undergo screening to confirm eligibility, then receive treatments according to randomization. Assessments include survival, progression-free survival, response rates, duration of response, and quality of life measured through questionnaires. Safety monitoring tracks adverse events and treatment delays or discontinuations. Follow-up includes safety visits and survival tracking, with total participation lasting up to approximately 46 months from start. The study is designed to monitor long-term outcomes and tolerability of these combinations in ES-SCLC treatment.
Actively Recruiting
Researchers are evaluating the combination of pumitamig also known as BNT327 or PM8002 with standard chemotherapy docetaxel in people with advanced or metastatic Non-small Cell Lung Cancer NSCLC that has progressed after first-line chemoimmunotherapy. This Phase II, multisite, open-label study aims to assess the safety and preliminary effectiveness of this combination treatment in this patient group. The study is designed in two parts to carefully monitor safety and expand dosing if appropriate. In Part 1, up to 12 participants will receive one of two dose levels of pumitamig combined with docetaxel in a safety run-in phase. Based on safety assessments, an internal review committee will decide whether to proceed to Part 2, where up to 54 additional participants will receive the recommended dose combination. In Part 2, some participants will also provide fresh tumor biopsy samples at baseline and during treatment for further analysis. Treatment continues until disease progression, unacceptable side effects, withdrawal, death, study end, or a 2-year limit. Participants will undergo regular assessments including safety monitoring for adverse events, dose adjustments, and tumor response using standard criteria. After treatment ends, a long-term follow-up will collect information on disease progression, new cancer treatments, and survival status. The primary outcomes focus on safety and response rates, while secondary outcomes include duration of response, progression-free survival, overall survival, and pharmacokinetics of pumitamig over approximately two years.
1-10 of 17
1